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Due to the prevalence of alkaloids in the chemical drug space and the broad range of 
biological properties held by the Aristotelia alkaloids, including anticancer properties, a library 
of structurally similar alkaloid-like compounds has been synthesised, containing the 3-aza-
bicyclo[3.3.1]nonane architecture, in order to explore the cytotoxicity of it and its derivatives. 
The 3-aza-bicyclo[3.3.1]nonane core was obtained via the bridged Ritter reaction with 
(-)-β-pinene and various nitriles to afford 18 compounds (Chapter 2). Several of the 
compounds obtained from the bridged Ritter reaction were derivatised to give an additional 17 
compounds (Chapter 3). The information obtained from these reaction outcomes, were used 
to further understand the bridged Ritter reaction mechanism. X-ray crystallography was used 
for analysis of the projection of the scaffold and substituents within the 3D space of the crystal 
lattice to further understand the reactivity of the synthesised scaffolds. 
The library of alkaloid-like compounds was tested for their biological properties. The 
breast cancer cell lines MDA-MB-231 and MCF-7 were investigated due to in-house data that 
showed activity for a related series of compounds (Chapter 4). The MDA-MB-231 cell line was 
tested in-house and 3 of 28 compounds showed significant activity in the reduction of cell 
viability, however, it is believed that they possess general toxicity, as opposed to having a 
cytotoxic nature. This library was deemed not viable for developing as cytotoxic agents within 
this project. 
Acetylcholine esterase (AChE) was chosen as an alternative target to be screened 
against (Chapter 5). Two complementary assays were used to determine the activity were 9 of 
the 27 tested compounds showed weak activity. SAR data and molecular modeling was used to 
develop a rational drug design approach to synthesise an improved inhibitor. Two of the 
designed compounds were synthesised and evaluated for their AChE inhibition properties and 
both showed relative increase in activity compared to their precursors. In addition to the 
docking studies used to guide the design of improved AChE inhibitors, molecular modeling was 
utilised to assess the drug-like properties and ADMET descriptors for each of the synthesised 
compounds. 
Lastly, broad screening of the biological properties of a selection of the synthesised 
compounds is currently being investigated by the services of the Lily OIDD program with 16 of 
the 31 submitted compounds are currently undergoing screening and results from five 
compounds have been returned so far. 
